Cargando…
Appraisal of Basic-Hemostatic Markers in Lung Cancer Patients During Follow-Up Care After Radiotherapy Treatment
BACKGROUND: The aim of this paper was to investigate the association between clinicopathological factors and the coagulation test in lung cancer patients during follow-up care after treatment. MATERIAL/METHODS: Ninety-five medical patients with histologically proven advanced lung carcinoma (LC) who...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278351/ https://www.ncbi.nlm.nih.gov/pubmed/30479323 http://dx.doi.org/10.12659/MSM.910280 |
_version_ | 1783378345641115648 |
---|---|
author | Wolny-Rokicka, Edyta I. Wydmański, Jerzy Tukiendorf, Andrzej Mróz, Piotr Zembroń-Łacny, Agnieszka |
author_facet | Wolny-Rokicka, Edyta I. Wydmański, Jerzy Tukiendorf, Andrzej Mróz, Piotr Zembroń-Łacny, Agnieszka |
author_sort | Wolny-Rokicka, Edyta I. |
collection | PubMed |
description | BACKGROUND: The aim of this paper was to investigate the association between clinicopathological factors and the coagulation test in lung cancer patients during follow-up care after treatment. MATERIAL/METHODS: Ninety-five medical patients with histologically proven advanced lung carcinoma (LC) who had undergone radiotherapy were prospectively reviewed between January 2014 and December 2016. The study investigated the relationship between the biochemical results, the disease stage, and the survival rate in lung cancer patients. Post-treatment coagulation-based D-dimer (DD), fibrinogen (Fib), and complete blood count (CBC) were evaluated during the follow-up over a period of 2 years after treatment or until the patient’s death. RESULTS: An increase of D-dimer generates an increased chance of early death by approximately 0.03% per 1 D-dimer unit. In cases when the difference in the D-dimer concentration equals 1000, the risk of an early death increases by (1.00031000−1)×100%=35%. CONCLUSIONS: High levels of D-dimer are associated with an advanced form of disease with metastasis and higher risk of early death in lung cancer patients. |
format | Online Article Text |
id | pubmed-6278351 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | International Scientific Literature, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-62783512018-12-27 Appraisal of Basic-Hemostatic Markers in Lung Cancer Patients During Follow-Up Care After Radiotherapy Treatment Wolny-Rokicka, Edyta I. Wydmański, Jerzy Tukiendorf, Andrzej Mróz, Piotr Zembroń-Łacny, Agnieszka Med Sci Monit Clinical Research BACKGROUND: The aim of this paper was to investigate the association between clinicopathological factors and the coagulation test in lung cancer patients during follow-up care after treatment. MATERIAL/METHODS: Ninety-five medical patients with histologically proven advanced lung carcinoma (LC) who had undergone radiotherapy were prospectively reviewed between January 2014 and December 2016. The study investigated the relationship between the biochemical results, the disease stage, and the survival rate in lung cancer patients. Post-treatment coagulation-based D-dimer (DD), fibrinogen (Fib), and complete blood count (CBC) were evaluated during the follow-up over a period of 2 years after treatment or until the patient’s death. RESULTS: An increase of D-dimer generates an increased chance of early death by approximately 0.03% per 1 D-dimer unit. In cases when the difference in the D-dimer concentration equals 1000, the risk of an early death increases by (1.00031000−1)×100%=35%. CONCLUSIONS: High levels of D-dimer are associated with an advanced form of disease with metastasis and higher risk of early death in lung cancer patients. International Scientific Literature, Inc. 2018-11-27 /pmc/articles/PMC6278351/ /pubmed/30479323 http://dx.doi.org/10.12659/MSM.910280 Text en © Med Sci Monit, 2018 This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) ) |
spellingShingle | Clinical Research Wolny-Rokicka, Edyta I. Wydmański, Jerzy Tukiendorf, Andrzej Mróz, Piotr Zembroń-Łacny, Agnieszka Appraisal of Basic-Hemostatic Markers in Lung Cancer Patients During Follow-Up Care After Radiotherapy Treatment |
title | Appraisal of Basic-Hemostatic Markers in Lung Cancer Patients During Follow-Up Care After Radiotherapy Treatment |
title_full | Appraisal of Basic-Hemostatic Markers in Lung Cancer Patients During Follow-Up Care After Radiotherapy Treatment |
title_fullStr | Appraisal of Basic-Hemostatic Markers in Lung Cancer Patients During Follow-Up Care After Radiotherapy Treatment |
title_full_unstemmed | Appraisal of Basic-Hemostatic Markers in Lung Cancer Patients During Follow-Up Care After Radiotherapy Treatment |
title_short | Appraisal of Basic-Hemostatic Markers in Lung Cancer Patients During Follow-Up Care After Radiotherapy Treatment |
title_sort | appraisal of basic-hemostatic markers in lung cancer patients during follow-up care after radiotherapy treatment |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278351/ https://www.ncbi.nlm.nih.gov/pubmed/30479323 http://dx.doi.org/10.12659/MSM.910280 |
work_keys_str_mv | AT wolnyrokickaedytai appraisalofbasichemostaticmarkersinlungcancerpatientsduringfollowupcareafterradiotherapytreatment AT wydmanskijerzy appraisalofbasichemostaticmarkersinlungcancerpatientsduringfollowupcareafterradiotherapytreatment AT tukiendorfandrzej appraisalofbasichemostaticmarkersinlungcancerpatientsduringfollowupcareafterradiotherapytreatment AT mrozpiotr appraisalofbasichemostaticmarkersinlungcancerpatientsduringfollowupcareafterradiotherapytreatment AT zembronłacnyagnieszka appraisalofbasichemostaticmarkersinlungcancerpatientsduringfollowupcareafterradiotherapytreatment |